SPY411.49+2.97 0.73%
DIA337.86+2.73 0.81%
IXIC13,900.19+70.88 0.51%

BRIEF-CSPC Pharmaceutical Dual Inhibitor Jak-Syk "Syhx1901" Gets Approval To Conduct Clinical Trials In China By NMPA

· 03/16/2021 11:10
BRIEF-CSPC Pharmaceutical Dual Inhibitor Jak-Syk "Syhx1901" Gets Approval To Conduct Clinical Trials In China By NMPA

- CSPC Pharmaceutical Group Ltd 1093.HK:

  • DUAL INHIBITOR JAK-SYK "SYHX1901" GETS APPROVAL TO CONDUCT CLINICAL TRIALS IN CHINA BY NMPA

Source text for Eikon: ID:nHKS6xvGPy

Further company coverage: 1093.HK


((reuters.briefs@thomsonreuters.com))